Castle Biosciences, Inc.
Castle Biosciences, Inc. (CSTL) Financial Performance & Income Statement Overview
Explore the financials of Castle Biosciences, Inc. (CSTL), including yearly and quarterly data on income, cash flow, and balance sheets.
Castle Biosciences, Inc. (CSTL) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Castle Biosciences, Inc. CSTL financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $87.99M | $86.31M | $85.78M | $87.002M |
| Cost of Revenue | $0.00 | $16.18M | $15.61M | $17.23M |
| Gross Profit | $87.99M | $70.13M | $70.17M | $69.77M |
| Gross Profit Ratio | $1.00 | $0.81 | $0.82 | $0.80 |
| R&D Expenses | $12.59M | $11.68M | $12.32M | $14.05M |
| SG&A Expenses | $58.62M | $49.97M | $50.50M | $50.71M |
| Operating Expenses | $115.92M | $66.08M | $65.09M | $64.76M |
| Total Costs & Expenses | $115.92M | $82.26M | $80.70M | $81.99M |
| Interest Income | $3.10M | $3.37M | $3.40M | $3.14M |
| Interest Expense | -$17000.00 | $92000.00 | $201000.00 | $270000.00 |
| Depreciation & Amortization | $0.00 | $5.77M | $3.54M | $3.35M |
| EBITDA | $0.00 | $13.74M | $12.02M | $11.50M |
| EBITDA Ratio | $0.00 | $0.16 | $0.14 | $0.13 |
| Operating Income | -$27.93M | $4.05M | $5.08M | $5.01M |
| Operating Income Ratio | -$0.32 | $0.05 | $0.06 | $0.06 |
| Other Income/Expenses (Net) | $1.66M | $3.83M | $3.20M | $2.87M |
| Income Before Tax | -$26.27M | $7.88M | $8.28M | $7.89M |
| Income Before Tax Ratio | -$0.30 | $0.09 | $0.10 | $0.09 |
| Income Tax Expense | -$423000.00 | -$1.71M | $6.01M | -$1.03M |
| Net Income | -$25.85M | $9.59M | $2.27M | $8.92M |
| Net Income Ratio | -$0.29 | $0.11 | $0.03 | $0.10 |
| EPS | -$0.90 | $0.34 | $0.08 | $0.32 |
| Diluted EPS | -$0.90 | $0.32 | $0.08 | $0.31 |
| Weighted Avg Shares Outstanding | $28.61M | $28.13M | $27.84M | $27.65M |
| Weighted Avg Shares Outstanding (Diluted) | $28.61M | $30.20M | $29.40M | $28.74M |
Financial performance has remained strong, with revenue growing from $87.002M in Q2 2024 to $87.99M in Q1 2025. Gross profit continued to perform well, with margins at 100% in the latest quarter. Operating income reached -$27.93M in Q1 2025, holding a steady -32% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $0.00. Net income dropped to -$25.85M, keeping EPS at -$0.90. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan